|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Mouse SPARC ORF mammalian expression plasmid, C-GFPSpark tag||MG50494-ACG|
|Mouse SPARC ORF mammalian expression plasmid, C-OFPSpark / RFP tag||MG50494-ACR|
|Mouse SPARC ORF mammalian expression plasmid, C-Flag tag||MG50494-CF|
|Mouse SPARC ORF mammalian expression plasmid, C-His tag||MG50494-CH|
|Mouse SPARC ORF mammalian expression plasmid, C-Myc tag||MG50494-CM|
|Mouse SPARC ORF mammalian expression plasmid, C-HA tag||MG50494-CY|
|Mouse SPARC Gene cDNA clone plasmid||MG50494-M|
|Mouse SPARC ORF mammalian expression plasmid, N-Flag tag||MG50494-NF|
|Mouse SPARC ORF mammalian expression plasmid, N-His tag||MG50494-NH|
|Mouse SPARC ORF mammalian expression plasmid, N-Myc tag||MG50494-NM|
|Mouse SPARC ORF mammalian expression plasmid, N-HA tag||MG50494-NY|
|Mouse SPARC natural ORF mammalian expression plasmid||MG50494-UT|
|Learn more about expression Vectors|
Secreted protein acidic and rich in cysteine (SPARC), also known as Osteonectin (ON), is a member of the SPARC family. SPARC consists of three domains: a EF-hand domain, a follistatin-like domain and a Kazal-like domain, and each of which has independent activity and unique properties. The activity of SPARC is context- and cell-type-dependent, which is highlighted by the fact that SPARC has shown seemingly contradictory effects on tumor progression in both clinical correlative studies and in animal models. The location of SPARC in the nuclear matrix of certain proliferating cells, but only in the cytosol of postmitotic neurons, indicates potential functions of SPARC as a nuclear protein, which might be involved in the regulation of cell cycle progression and mitosis. It functions not only to modulate cell-cell and cell-matrix interactions, but its de-adhesive and growth inhibitory properties in non-transformed cells have led to studies to assess its role in cancer. Its divergent actions reflect the complexity of this protein, because in certain types of cancers, such as melanomas and gliomas, SPARC is associated with a highly aggressive tumor phenotype, while in others, mainly ovarian, neuroblastomas and colorectal cancers, SPARC may function as a tumor suppressor. Recent studies have also demonstrated a role for SPARC in sensitizing therapy-resistant cancers. Notably, SPARC is linked to human obesity.